- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03801980
Phase 3 Study of SK-1403
March 6, 2020 updated by: Sanwa Kagaku Kenkyusho Co., Ltd.
Phase 3 Study of SK-1403 ; Double-blinded Parallel Group in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis
To evaluate the efficacy and safety of treatment with SK-1403 for 24 weeks in patients with secondary hyperparathyroidism on maintenance hemodialysis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
153
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan
- Investigational site (there may be other sites in this country)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Serum PTH>240 pg/mL at the screening
- Serum corrected Ca≧8.4 mg/dL at the screening
- Stable chronic kidney disease patients who undergo hemodialysis or hemodialysis filtration
Exclusion Criteria:
- Primary hyperparathyroidism
- Severe liver disease
- Severe Cardiac disease
- History or family history of long QT syndrome
- Malignant tumor
- Uncontrolled diabetes mellitus
- Uncontrolled hypertension
- History of severe drug allergy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SK-1403
Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
|
Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
|
PLACEBO_COMPARATOR: Placebo
Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
|
Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of participants who achieved a mean serum iPTH level of ≥ 60 pg/mL and ≤ 240 pg/mL from 22 to 24 week.
Time Frame: 24 weeks
|
Assessed by laboratory test value
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of participants who achieved a serum iPTH level of ≥ 60 pg/mL and ≤ 240 pg/mL at each time point.
Time Frame: 24 weeks
|
Assessed by laboratory test value
|
24 weeks
|
Measured values and Changes from baseline in serum PTH
Time Frame: 24 weeks
|
Assessed by laboratory test value; unit of measure (pg/mL)
|
24 weeks
|
Measured values and Changes from baseline in Ca
Time Frame: 24 weeks
|
Assessed by laboratory test value; unit of measure (mg/dL)
|
24 weeks
|
Measured values and Changes from baseline in ionized Ca
Time Frame: 24 weeks
|
Assessed by laboratory test value; unit of measure (mEq/dL)
|
24 weeks
|
Measured values and Changes from baseline in P
Time Frame: 24 weeks
|
Assessed by laboratory test value; unit of measure (mg/dL)
|
24 weeks
|
Measured values and Changes from baseline in serum Ca x P product
Time Frame: 24 weeks
|
Assessed by laboratory test value
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 21, 2019
Primary Completion (ACTUAL)
December 17, 2019
Study Completion (ACTUAL)
December 21, 2019
Study Registration Dates
First Submitted
January 8, 2019
First Submitted That Met QC Criteria
January 9, 2019
First Posted (ACTUAL)
January 14, 2019
Study Record Updates
Last Update Posted (ACTUAL)
March 9, 2020
Last Update Submitted That Met QC Criteria
March 6, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AJ1004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Secondary Hyperparathyroidism
-
The Second Hospital of Nanjing Medical UniversityRecruitingSecondary Hyperparathyroidism;ParathyroidectomyChina
-
Chang Gung Memorial HospitalCompletedSecondary Hyperparathyroidism Due to Renal CausesTaiwan
-
Fundación SenefroAbbVie; Effice Servicios Para la Investigacion S.L.CompletedSecondary Hyperparathyroidism Due to Renal CausesSpain
-
Phramongkutklao College of Medicine and HospitalCompletedAlfacalcidol, Secondary Hyperparathyroidism, Hemodialysis
-
Min-Sheng General HospitalTaipei Medical University; Taipei Medical University Shuang Ho Hospital; National... and other collaboratorsCompletedHyperparathyroidism; Secondary, RenalTaiwan
-
Shanghai Zhongshan HospitalUnknownHyperparathyroidism; Secondary, Renal
-
Kyowa Kirin Co., Ltd.CompletedHyperparathyroidismJapan
-
Centre Hospitalier Universitaire de Saint EtienneUniversity Hospital, GenevaCompleted
-
China-Japan Friendship HospitalRecruitingSecondary HyperparathyroidismChina
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin China Pharmaceutical Co., LTD.; Kyowa Kirin Korea Co., Ltd.CompletedSecondary HyperparathyroidismChina, Hong Kong, Korea, Republic of, Taiwan
Clinical Trials on SK-1403
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedSecondary HyperparathyroidismJapan
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedSecondary HyperparathyroidismJapan
-
Anterios Inc.CompletedPrimary Axillary HyperhidrosisUnited States
-
ModernaTX, Inc.Active, not recruitingNorovirus Acute GastroenteritisUnited States
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedUremic Pruritus in Hemodialysis PatientsJapan
-
Kowa Research Institute, Inc.CompletedType 2 Diabetes MellitusUnited States
-
Sanwa Kagaku Kenkyusho Co., Ltd.Completed
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedNocturia Due to Nocturnal PolyuriaJapan
-
SK Chemicals Co., Ltd.CompletedErosive GastritisKorea, Republic of
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedPruritusUnited Kingdom